Medexus Holds Annual Meeting of Shareholders and Announces Election of Directors
Medexus Pharmaceuticals (OTCQX:MEDXF) successfully conducted its virtual annual shareholders meeting, where all proposed directors were elected for the upcoming term. The shareholders demonstrated strong support for the board nominees, with approval ratings ranging from 92.19% to 96.45%.
Additionally, shareholders overwhelmingly approved the appointment of PricewaterhouseCoopers LLP as the company's auditors with 99.51% of votes in favor. The voting results will be filed with Canadian securities regulatory authorities.
Medexus Pharmaceuticals (OTCQX:MEDXF) ha condotto con successo la sua riunione annuale degli azionisti in forma virtuale, durante la quale sono stati eletti tutti i direttori proposti per il prossimo mandato. Gli azionisti hanno mostrato un forte sostegno ai candidati al consiglio, con percentuali di approvazione comprese tra 92,19% e 96,45%.
Inoltre, gli azionisti hanno approvato all'unanimità la nomina di PricewaterhouseCoopers LLP come revisori della società con 99,51% dei voti favorevoli. I risultati del voto saranno depositati presso le autorità regolamentari sui titoli canadesi.
Medexus Pharmaceuticals (OTCQX:MEDXF) llevó a cabo con éxito su junta anual de accionistas de forma virtual, donde se eligieron todos los directores propuestos para el próximo periodo. Los accionistas mostraron un fuerte respaldo a los candidatos de la junta, con aprobaciones entre 92,19% y 96,45%.
Además, los accionistas aprobaron por abrumadora mayoría la designación de PricewaterhouseCoopers LLP como auditores de la empresa con 99,51% de los votos a favor. Los resultados de la votación se presentarán a las autoridades regulatorias de valores canadienses.
Medexus Pharmaceuticals (OTCQX:MEDXF)는 가상으로 진행된 연례 주주총회를 성공적으로 개최했으며, 차기 임기 동안 제안된 모든 이사가 선출되었습니다. 주주는 이사회 후보들에 대해 92.19%에서 96.45%의 지지를 보였습니다.
또한 주주들은 회사의 감사로 PricewaterhouseCoopers LLP를 지명하는 것을 압도적으로 승인했고 찬성은 99.51%였습니다. 표 결과는 캐나다 증권 규제 당국에 제출될 예정입니다.
Medexus Pharmaceuticals (OTCQX:MEDXF) a mené avec succès sa réunion annuelle des actionnaires en visioconférence, au cours de laquelle tous les administrateurs proposés ont été élus pour le prochain mandat. Les actionnaires ont manifesté un fort soutien envers les candidats au conseil, avec des taux d'approbation allant de 92,19% à 96,45%.
De plus, les actionnaires ont approuvé à une large majorité la nomination de PricewaterhouseCoopers LLP comme auditeurs de la société avec 99,51% des voix. Les résultats du vote seront déposés auprès des autorités de réglementation des valeurs mobilières canadiennes.
Medexus Pharmaceuticals (OTCQX:MEDXF) hat erfolgreich seine virtuelle Hauptversammlung der Aktionäre durchgeführt, bei der alle vorgeschlagenen Direktoren für die kommende Amtszeit gewählt wurden. Die Aktionäre zeigten starke Unterstützung für die Kandidaten des Vorstands, mit Zustimmungswerten von 92,19% bis 96,45%.
Außerdem haben die Aktionäre die Ernennung von PricewaterhouseCoopers LLP als Prüfungsgesellschaft des Unternehmens mit 99,51% der Stimmen eindeutig gebilligt. Die Abstimmungsergebnisse werden den kanadischen Wertpapieraufsichtsbehörden vorgelegt.
Medexus Pharmaceuticals (OTCQX:MEDXF) عقدت بنجاح اجتماع المساهمين السنوي الافتراضي، حيث تم انتخاب جميع المدراء المقترحين للفترة القادمة. أظهر المساهمون دعمًا قويًا للمترشحين للمجلس، بمعدلات موافقة تراوحت بين 92.19% و 96.45%.
بالإضافة إلى ذلك، وافق المساهمون بأغلبية ساحقة على تعيين PricewaterhouseCoopers LLP كمدققين للشركة بحصولهم على 99.51% من الأصوات المؤيدة. سيتم تقديم نتائج التصويت إلى الجهات التنظيمية الكندية للأسهم.
Medexus Pharmaceuticals (OTCQX:MEDXF) 成功召开了公司的线上年度股东大会，所有提名的董事均已在下任期当选。股东对董事会提名人表现出强烈支持，赞成率介于92.19%至96.45%之间。
此外，股东以压倒性多数通过任命 PricewaterhouseCoopers LLP 作为公司的审计师，赞成票为99.51%。投票结果将提交给加拿大证券监管机构。
- None.
- None.
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - September 25, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today held its virtual annual meeting of shareholders. Medexus shareholders elected all nominees listed in Medexus's management information circular dated August 12, 2025 as directors through the next annual meeting. Shareholders also voted in favor of the appointment of PricewaterhouseCoopers LLP as the company's auditors.
Detailed voting results for the election of directors are set out in the table below.
| Name | For | Against |
| Ken d'Entremont | ||
| Harmony Garges | ||
| Benoit Gravel | ||
| Michael Mueller | ||
| Stephen Nelson | ||
| Nancy Phelan | ||
| Menassie Taddese |
Shareholders also cast 14,240,037 (
A report of the voting results on all matters voted on at the annual meeting will be filed with Canadian securities regulatory authorities at www.sedarplus.ca.
About Medexus
Medexus is a leading specialty pharmaceutical company with a strong North American commercial platform and a growing portfolio of innovative and rare disease treatment solutions. Medexus's current focus is on the therapeutic areas of hematology and hematology-oncology and allergy, dermatology, and rheumatology. For more information about Medexus and its product portfolio, please see the company's corporate website at www.medexus.com and its filings on SEDAR+ at www.sedarplus.ca.
Contacts
Ken d'Entremont | CEO, Medexus Pharmaceuticals
Tel: 905-676-0003 | Email: ken.dentremont@medexus.com
Brendon Buschman | CFO, Medexus Pharmaceuticals
Tel: 416-577-6216 | Email: brendon.buschman@medexus.com
Victoria Rutherford | Adelaide Capital
Tel: 480-625-5772 | Email: victoria@adcap.ca
Forward-looking statements
Certain statements made in this news release contain forward-looking information within the meaning of applicable securities laws, also known and/or referred to as "forward-looking information" or "forward-looking statements". The words "anticipates", "believes", "expects", "will", "plans", "potential", and similar words, phrases, or expressions are often intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words, phrases, or expressions. These statements are based on factors or assumptions that were applied in drawing a conclusion or making a forecast or projection, including assumptions based on regulatory guidelines, historical trends, current conditions, and expected future developments. Since forward-looking statements relate to future events and conditions, by their very nature they require making assumptions and involve inherent risks and uncertainties. Medexus cautions that, although the assumptions are believed to be reasonable in the circumstances, these risks and uncertainties mean that actual results could differ, and could differ materially, from the expectations contemplated by the forward-looking statements. Material risk factors include, but are not limited to, those set out in Medexus's materials filed with the Canadian securities regulatory authorities from time to time, including Medexus's most recent annual information form and management's discussion and analysis. Accordingly, undue reliance should not be placed on these forward-looking statements, which are made only as of the date of this news release. Other than as specifically required by law, Medexus undertakes no obligation to update any forward-looking statements to reflect new information, subsequent or otherwise.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/268018
FAQ
Who are the newly elected directors of Medexus Pharmaceuticals (MEDXF)?
What was the voting result for Medexus (MEDXF) auditor appointment?
Which Medexus (MEDXF) director received the highest shareholder approval?
When was Medexus Pharmaceuticals' 2025 annual shareholder meeting held?
